Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL612879 Target Snapshot

Leishmania major · ORGANISM · Leishmania major

Back to Search Search this target Browse approvals Evidence Card
2,067Compounds
392Assays
28Approved Drugs
2,488.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Leishmania major as ChEMBL target CHEMBL612879. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Leishmania major
ORGANISM · Leishmania major
As of 2026-09-14
ChEMBL target ID
CHEMBL612879
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Leishmania major still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameLeishmania major
Target TypeORGANISM
OrganismLeishmania major
ChEMBL ↗ NCBI Taxonomy ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelLeishmania major
UniProt AccessionN/A

Leishmania major

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Leishmania major.

Review nameLeishmania major
OrganismLeishmania major
Clinical Profile

Clinical Phase Distribution

28
Approved
7
Phase III
1
Phase I
Assay Mix

Activity Type Distribution

IC501,718.0
EC50770.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL267345 10.46 IC50 0.035 Approved
CHEMBL2071225 10.28 IC50 0.053 Preclinical
CHEMBL2071223 9.82 IC50 0.15 Preclinical
CHEMBL2071226 9.74 IC50 0.18 Preclinical
CHEMBL4594805 8.7 IC50 2.0 Preclinical
CHEMBL1275764 7.85 IC50 14.0 Preclinical
CHEMBL1276549 7.58 IC50 26.0 Preclinical
CHEMBL37644 7.52 IC50 30.0 Preclinical
CHEMBL5281090 7.52 IC50 30.1 Preclinical
CHEMBL5423282 7.52 IC50 30.0 Preclinical
Distribution

pChEMBL Value Distribution

382
5.0
247
5.5
169
6.0
60
6.5
18
7.0
10
7.5
0
8.0
1
8.5
0
9.0
2
9.5
pChEMBL
Approved Drugs

Approved Drugs

ITRACONAZOLE
CHEMBL64391
Approved 1992
Properties Compare Identifier
PENTAMIDINE
CHEMBL55
Approved 1984
Properties Compare Identifier
KETOCONAZOLE
CHEMBL157101
Approved 1981
Properties Compare Identifier
DAUNORUBICIN
CHEMBL178
Approved 1979
Properties Compare Identifier
AMPHOTERICIN B
CHEMBL267345
Approved 1964
Properties Compare Identifier
FURAZOLIDONE
CHEMBL1103
Approved 1958
Properties Compare Identifier
METHOTREXATE
CHEMBL34259
Approved 1953
Properties Compare Identifier
Assay Landscape

Assay Landscape

395
Total Assays
1,059
Tested Compounds
2
Assay Types
Functional — 382 assays, 1,059 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 366 991 5.3
assay format 13 36 5.4
cell-based format 3 32 4.9
ADME — 13 assays, 9 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 13 9 4.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine